TRANSVERSAL PATCH ON HUNTINGTONS DISEASES

Huntington's disease (HD) is a progressive neurodegenerative disorder marked by motor impairment, cognitive decline, and psychiatric symptoms. Deutetrabenazine, a deuterated analog of tetrabenazine, is an FDA-approved medication that alleviates chorea in HD patients by inhibiting vesicular monoamine transporter 2 (VMAT2), which modulates dopamine levels in the brain. However, oral administration of Deutetrabenazine can result in variable drug absorption, fluctuating plasma concentrations, and gastrointestinal side effects, posing challenges for consistent management of symptoms. This study investigates a novel transversal approach to enhance Deutetrabenazine delivery using a transdermal patch. The proposed transdermal delivery system aims to provide a continuous, controlled release of Deutetrabenazine, improving pharmacokinetics, reducing peak-trough fluctuations, and enhancing patient compliance. Furthermore, the transdermal patch may be designed to co-deliver complementary therapeutic agents targeting other disease aspects, such as neuroprotection or inflammation, to offer a multimodal treatment strategy. This research explores the feasibility, effectiveness, and patient acceptability of this transdermal system, with the potential to provide more consistent symptom control and address the underlying neurodegenerative processes of Huntington's disease.